FDA highlights approvals in 2018 at recent ASH meeting in San Diego. 2018 saw 32 FDA approvals in hematology including 12 NMEs & 5 biosimilars. 8 had pediatric indications. 6 were for 1st-line indications. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm #FDA #Approvals #hematology #oncology #2018

Top 10 oncology companies by 2024 per FiercePharma

A new study recently published in Value in Health by Risha Gidwani-Marszowski, DrPH, a health economist at the VA Palo Alto Health Care System and at Stanford. Click image to read full article Image by Nick Youngson "One of the most interesting things we found through this work is that the divergent views exist at a very basic level — the definition of value. For example, in defini

EvaluatePharma projects the best sellers of 2018. #2018 #drugs #pharmaceuticals #oncology